Pharmacokinetics and safety of a single dose of the novel LAMA/LABA fixed-dose combination of glycopyrronium/formoterol fumarate dihydrate metered dose inhaler, formulated using co-suspension delivery technology, in Japanese healthy subjects

Pulmonary Pharmacology & Therapeutics
Colin ReisnerUbaldo J Martin

Abstract

Chronic obstructive pulmonary disease (COPD) causes significant mortality in Japan. GFF MDI is a long-acting muscarinic antagonist/long-acting β2-agonist fixed-dose combination of glycopyrronium (GP) and formoterol fumarate dihydrate (FF), delivered by a metered dose inhaler (MDI) using co-suspension delivery technology, for the long-term maintenance treatment of COPD. This randomized, Phase I, single-dose, four-treatment, four-period, crossover study (NCT02196714) examined the pharmacokinetic (PK) and safety profile of two doses of GFF MDI (28.8 μg/10 μg and 14.4 μg/10 μg) and two doses of GP MDI (28.8 μg and 14.4 μg), both formulated using co-suspension delivery technology, in healthy Japanese subjects (18-45 years of age). PK parameters included area under the curve (AUC) from 0 to 12 h (AUC0-12), AUC from 0 to the time of the last measurable plasma concentration, maximum observed plasma concentration (Cmax), and time to Cmax. Safety was monitored throughout the study. Plasma GP profiles were comparable between GFF MDI and GP MDI formulations containing the same GP dose. Increases in GP AUC0-12 and Cmax were generally dose proportional from 14.4 to 28.8 μg after administration of either formulation. The addition of FF 10 μg ...Continue Reading

Associated Clinical Trials

References

Dec 23, 2004·Respirology : Official Journal of the Asian Pacific Society of Respirology·Yoshinosuke FukuchiCarol Zaher
Jun 19, 2007·American Journal of Respiratory and Critical Care Medicine·Nanshan ZhongPixin Ran
Oct 19, 2007·The Journal of Asthma : Official Journal of the Association for the Care of Asthma·Timothy H SelfHeather Swanson
Jun 11, 2008·Clinical Cardiology·Akira FunadaMasakazu Yamagishi
Jul 11, 2008·Clinical Pharmacology and Therapeutics·S U YasudaS-M Huang
Jan 16, 2009·Respirology : Official Journal of the Asian Pacific Society of Respirology·Wan C TanNan-Shan Zhong
Jan 1, 2010·Basic & Clinical Pharmacology & Toxicology·Achiel Van Peer
Jan 20, 2012·International Journal of Clinical Pharmacology and Therapeutics·Romain SechaudGuenther Kaiser
Jun 1, 2013·The European Respiratory Journal·Eric D BatemanDonald Banerji
Jul 9, 2013·Respiratory Medicine·J F DonohueA Church
Jan 13, 2015·The European Respiratory Journal·Roland BuhlEric Bateman
Aug 11, 2015·Annals of Internal Medicine·Wendy P BattistiYvonne E Yarker

❮ Previous
Next ❯

Related Concepts

Related Feeds

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.